Your browser doesn't support javascript.
loading
Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation.
Patel, Sagar S; Ahn, Kwang Woo; Khanal, Manoj; Bupp, Caitrin; Allbee-Johnson, Mariam; Majhail, Navneet S; Hamilton, Betty K; Rotz, Seth J; Hashem, Hasan; Beitinjaneh, Amer; Lazarus, Hillard M; Krem, Maxwell M; Prestidge, Tim; Bhatt, Neel S; Sharma, Akshay; Gadalla, Shahinaz M; Murthy, Hemant S; Broglie, Larisa; Nishihori, Taiga; Freytes, César O; Hildebrandt, Gerhard C; Gergis, Usama; Seo, Sachiko; Wirk, Baldeep; Pasquini, Marcelo C; Savani, Bipin N; Sorror, Mohamed L; Stadtmauer, Edward A; Chhabra, Saurabh.
Afiliação
  • Patel SS; Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Ahn KW; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Khanal M; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Bupp C; Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
  • Allbee-Johnson M; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Majhail NS; Sarah Cannon, Nashville, Tennessee.
  • Hamilton BK; Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
  • Rotz SJ; Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic Children's Hospital, Cleveland, Ohio.
  • Hashem H; Division of Pediatric Hematology/Oncology and Bone marrow Transplantation, King Hussein Cancer Center, Amman, Jordan.
  • Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, Florida.
  • Lazarus HM; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.
  • Krem MM; Kansas City VA Medical Center, Kansas City, Missouri.
  • Prestidge T; Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand.
  • Bhatt NS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Gadalla SM; Division of Cancer Epidemiology & Genetics, National Cancer Institute, Clinical Genetics Branch, Rockville, Maryland.
  • Murthy HS; Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.
  • Broglie L; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Nishihori T; Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
  • Freytes CO; University of Texas Health Science Center at San Antonio, San Antonio, Texas.
  • Hildebrandt GC; Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
  • Gergis U; Department of Medical Oncology, Division of Hematological Malignancies, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • Seo S; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
  • Wirk B; Bone Marrow Transplant Program, Penn State Cancer Institute, Hershey, Pennsylvania.
  • Pasquini MC; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Sorror ML; Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington; Departments of Pediatrics and Medicine, University of Washington School of Medicine, Seattle, Washington.
  • Stadtmauer EA; University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.
  • Chhabra S; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: schhabra@mcw.edu.
Transplant Cell Ther ; 28(6): 310-320, 2022 06.
Article em En | MEDLINE | ID: mdl-35314376
ABSTRACT
Noninfectious pulmonary toxicity (NPT), a significant complication of allogeneic hematopoietic cell transplantation (alloHCT), includes idiopathic pneumonia syndrome (IPS), diffuse alveolar hemorrhage (DAH), and cryptogenic organizing pneumonia (COP), with an overall incidence ranging from 1% to 15% in different case series and a variable mortality rate. A registry study of the epidemiology and outcomes of NPT after alloHCT has not been conducted to date. The primary objective of the present study was to assess the incidence of and risk factors for IPS, DAH, and COP; the secondary objective was to assess overall survival (OS) in patients developing NPT. This retrospective study included adult patients who underwent alloHCT between 2008 and 2017 and reported to the Center for International Blood and Marrow Transplant Research. Multivariable Cox proportional hazards regression models were developed to identify the risk factors for development of NPT and for OS, by including pretransplantation clinical variables and time-dependent variables of neutrophil and platelet recovery, and acute graft-versus-host disease (GVHD) post-transplantation. This study included 21,574 adult patients, with a median age of 55 years. According to the HCT Comorbidity Index (HCT-CI), 24% of the patients had moderate pulmonary comorbidity and 15% had severe pulmonary comorbidity. The cumulative incidence of NPT at 1 year was 8.1% (95% confidence interval [CI], 7.7% to 8.5%). Individually, the 1-year cumulative incidences of IPS, DAH, and COP were 4.9% (95% CI, 4.7% to 5.2%), 2.1% (95% CI, 1.9% to 2.3%), and .7% (95% CI, .6% to .8%), respectively. Multivariable analysis showed that severe pulmonary comorbidity, grade II-IV acute GVHD, mismatched unrelated donor and cord blood transplantation, and HCT-CI score ≥1 significantly increased the risk of NPT. In contrast, alloHCT performed in 2014 or later, non-total body irradiation (TBI)- and TBI-based nonmyeloablative conditioning and platelet recovery were associated with a decreased risk. In a landmark analysis at day+100 post-transplantation, the risk of DAH was significantly lower in patients who had platelet recovery by day +100. Multivariable analysis for OS demonstrated that NPT significantly increased the mortality risk (hazard ratio, 4.2; P < .0001).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro / Pneumopatias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Middle aged Idioma: En Revista: Transplant Cell Ther Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro / Pneumopatias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Middle aged Idioma: En Revista: Transplant Cell Ther Ano de publicação: 2022 Tipo de documento: Article